Novartis: positive data for Fabhalta in HPN

(CercleFinance.com) - Novartis reports data from the APPULSE-PNH phase IIIB study, showing that its Fabhalta improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) previously on anti-C5 therapy.


PNH is a rare, chronic and severe complement-mediated blood disorder characterized by hemolysis, anemia, thrombosis and other symptoms. Patients are often treated with anti-C5 therapies.

Data will be presented at an upcoming medical meeting in 2025. Fabhalta recently received accelerated approval from the US FDA for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy.


Copyright (c) 2024 CercleFinance.com. All rights reserved.